Skip to main content
. 2026 Oct 4;18(19):3205. doi: 10.3390/cancers18193205
ABVD doxorubicin–bleomycin–vinblastine–dacarbazine
AUC area under the receiver operating characteristic curve
CALLY C-reactive protein–albumin–lymphocyte
CI confidence interval
CRP C-reactive protein
ESR erythrocyte sedimentation rate
18F-FDG 18F-fluorodeoxyglucose
HR hazard ratio
IPS International Prognostic Score
IQR interquartile range
LMR lymphocyte-to-monocyte ratio
NLR neutrophil-to-lymphocyte ratio
OR odds ratio
OS overall survival
PET/CT positron emission tomography/computed tomography
PFS progression-free survival
PLR platelet-to-lymphocyte ratio